Caris Life Sciences, a pioneering AI TechBio company, announced plans to present three innovative research studies at the upcoming 2025 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, scheduled for February 13-15 in San Francisco. The research presentations, developed in collaboration with members of the Caris Precision Oncology Alliance™ (POA), focus on advancing precision medicine in genitourinary cancers.
"We are proud to present innovative research for prostate cancer and urothelial carcinoma at the upcoming ASCO GU meeting," said Dr. James Hamrick, MPH, Chairman of the Caris Precision Oncology Alliance. "Through our comprehensive molecular profiling, powerful database and in-depth collaboration with Caris POA members, we are pushing the boundaries of precision medicine and helping improve outcomes for cancer patients."
Research Highlights
The company will present three distinct poster sessions highlighting different aspects of genitourinary cancer research:
The first study examines molecular alteration profiles to distinguish intraductal carcinoma of the prostate, offering potential insights into more accurate diagnosis and treatment planning. This research will be presented during Poster Session A on February 13.
A second study investigates the downregulation of E-selectin and its contributions to immune restraining in prostate cancer, potentially opening new avenues for therapeutic intervention. This presentation is also scheduled for Poster Session A.
The third study presents a real-world analysis of the 2IR immune response score in urothelial carcinoma, which could have significant implications for patient care and treatment selection. This research will be presented during Poster Session B on February 14.
Advancing Precision Medicine Through Collaboration
The research presentations underscore the strength of the Caris Precision Oncology Alliance, a collaborative network comprising 96 cancer centers, academic institutions, research consortia, and healthcare systems. Among these, 47 are NCI-designated cancer centers, highlighting the alliance's commitment to excellence in cancer research and treatment.
The studies leverage Caris' comprehensive molecular profiling capabilities, which include Whole Exome and Whole Transcriptome Sequencing, combined with advanced AI and machine learning algorithms. This technological convergence has enabled the creation of a large-scale, multimodal database that helps unravel the molecular complexity of disease.
Impact on Patient Care
These research presentations represent significant steps forward in understanding genitourinary cancers and developing more personalized treatment approaches. The findings could potentially influence how healthcare providers diagnose, prognosticate, and treat patients with prostate cancer and urothelial carcinoma.
Detailed poster and abstract summaries will be available at Caris' booth (#32) during the symposium, with full abstracts becoming accessible on the Caris website beginning February 13.
